About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Press Releases
Biocon Biologics
/
News – Posts
/
Press Releases
Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
Tue, 23-May-2023
Posted by: Biocon Biologics
No Comments
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
Fri, 28-Apr-2023
Posted by: Biocon Biologics
No Comments
Serum & Biocon Biologics Agree to Restructure Equity Investment
Tue, 25-Apr-2023
Posted by: Biocon Biologics
No Comments
Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments
Mon, 03-Apr-2023
Posted by: Biocon Biologics
No Comments
Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
Tue, 28-Mar-2023
Posted by: Biocon Biologics
No Comments
Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%
Thu, 09-Mar-2023
Posted by: Biocon Biologics
No Comments
Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
Thu, 22-Dec-2022
Posted by: Biocon Biologics
No Comments
Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Mon, 05-Dec-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
Tue, 29-Nov-2022
Posted by: Biocon Biologics
No Comments
Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
Tue, 15-Nov-2022
Posted by: Biocon Biologics
No Comments
1
2
3
…
16